Drug intelligence / Profile preview

duloxetine vs. escitalopram

Development stage
Unknown
Lead developer
Eli Lilly
Modality
Small Molecules
Administration
Oral
01

Overview

Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used primarily for the treatment of major depressive disorder, generalized anxiety disorder, and certain types of pain such as neuropathic pain and fibromyalgia. It works by inhibiting the reuptake of both serotonin and norepinephrine in the central nervous system, thereby increasing their levels and enhancing neurotransmission[1][5][8]. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) indicated for major depressive disorder and generalized anxiety disorder. It selectively inhibits the serotonin transporter (SERT), leading to increased synaptic concentrations of serotonin. Escitalopram also binds to an allosteric site on SERT, which may further modulate its activity[6]. Both drugs are prescription antidepressants with established efficacy in depression and anxiety disorders; duloxetine has broader FDA-approved uses including pain syndromes, while escitalopram is noted for its high selectivity for SERT and generally favorable tolerability profile[3][5].

Brand names
CymbaltaDrizalma SprinkleIrenkaLexapro
02

Targets

NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on duloxetine vs. escitalopram.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on duloxetine vs. escitalopram.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call